The tools needed to diagnose, treat and develop new therapies Precision medicine is medical care that uses genetic and molecular profiling to optimise treatment for specific groups of patients. KMPMJ is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. (Konica Minolta) started the operations of Konica Minolta Precision Medicine Japan, Inc. Visit for more information.On October 1, 2018, Konica Minolta, Inc. Along with their sister company, Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs.
Invicro’s quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®. Invicro’s multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drugs across all stages of the drug development pipeline (Phase 0-IV), leveraging all modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and immunology. Headquartered in Boston, MA, Invicro was founded in 2008 with offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology and top research universities. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. that includes Ambry Genetics Corporation and Invicro LLC. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. Under his leadership, that spirit of continuous improvement will further the success of Ambry.” “His implementation of a Learning & Development department and a talent management program has had far reaching impact throughout the company. “In addition to Tom’s solid track record for driving business growth and market share, he has the keen ability to understand organizational gaps and implement best-in-class processes,” added Fujii. Under his leadership, go-to-market execution of programs such as Ambry’s CARE and +RNAInsight ® have resulted in double-digit growth into new specialty segments and increased active ordering physicians to over 9,500+. Schoenherr joined Ambry in 2017 as Chief Commercial Officer and was responsible for Ambry’s commercial expansion strategy that has more than doubled Ambry’s business and test volumes.
KMPM also announced that Tom Schoenherr has been named Chief Executive Officer of Ambry Genetics. “I have been especially impressed with the award-winning culture of employee inclusivity and opportunity that Aaron has fostered at Ambry and anticipate this continuation throughout KMPM.”
“Aaron’s exemplary leadership and command of clinical innovation make him the right person to lead KMPM into the future,” said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta, Inc. Elliott also served as Chief Operating Officer and Chief Scientific Officer, and saw the company through many trailblazing milestones including numerous novel first to market diagnostic tests, the landmark BRCA gene patent case which opened up genetic testing in the United States and the acquisition by Konica Minolta. Elliott will be responsible for driving execution across all KMPM business units, which include Ambry Genetics, Invicro, and KMPM-Japan.
The changes reflect a thoughtful and strategic approach to the next phase of growth and expansion for the global precision diagnostics organization.Īaron Elliott, current CEO of Ambry Genetics, has been named Chief Executive Officer of KMPM.
(KMPM) announced today changes to its executive leadership team effective immediately. Aliso Viejo, CA., Konica Minolta Precision Medicine, Inc.